Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Regular meals important for the health

It is obvious to most people that our health is affected by what we eat; now, however, scientists have shown that it is also a matter of how often we eat.

21 Jul 2008

Lipid Association responds to new cholesterol guidelines for kids

When the American Academy of Pediatrics (AAP) issued its recommendation on July 7 regarding the treatment of children with high cholesterol, it generated a strong response from the community of medical professionals and patients. The National Lipid Association (NLA), a group of healthcare professionals who specialize in cholesterol and heart disease issues, believes that the AAP has acted in the interests of patient care by raising the issue of lipid abnormalities in children.

10 Jul 2008

Erection problems may signal serious heart disease

Erectile dysfunction is always a matter of the heart, but new research shows that more than romance is at stake. Two new studies of men with type 2 diabetes found that erectile dysfunction (ED) was a powerful early warning sign for serious heart disease, including heart attack and death.

19 May 2008

Tredaptive and Janumet recommended for approval in European Union

Food and Drug Administration (FDA) is currently reviewing the combination of extended release (ER) niacin and laropiprant under the trademark Cordaptive (ER niacin/laropiprant). The CHMP recommendation does not apply to regulatory decisions by the FDA and no inferences should be made about pending FDA regulatory actions based on the recommendation of the CHMP.

24 Apr 2008

Lower target levels for blood pressure, LDL-cholesterol may provide cardiovascular benefits

Patients with diabetes who reduced their blood pressure and LDL-cholesterol to below standard target levels had a greater decrease in carotid artery wall thickness, but did not have a significant difference in cardiovascular disease events than patients who had recommended blood pressure and LDL-cholesterol levels, according to a study in the April 9 issue of JAMA, the Journal of the American Medical Association.

9 Apr 2008

Genetic variants of USF1 are associated with the increased risk for cardiovascular disease

Cardiovascular diseases (CVD) are major contributors to morbidity and mortality worldwide.

8 Apr 2008

Monthly contact with counselor provides some benefit for maintaining weight loss

Weight-loss program participants who had a brief, monthly personal contact intervention - most often a 10-15 minute phone conversation - regained less weight than participants who were in a Web-based intervention or self-directed program, according to a study in the March 12 issue of JAMA, the Journal of the American Medical Association.

12 Mar 2008

New potential drug target for atherosclerosis

A nuclear receptor protein, known for controlling the ability of cells to burn fat, also exerts powerful anti-inflammatory effects in arteries, suppressing atherosclerosis in mice prone to developing the harmful plaques, according to new research by scientists at the Salk Institute for Biological Studies and the Harvard School of Public Health.

6 Mar 2008

Testosterone supplementation in older men

Older men with low testosterone levels who received testosterone supplementation increased lean body mass and decreased body fat, but were no stronger and had no improvement in mobility or cognition compared with men who did not use the supplement, according to a study in the January 2 issue of JAMA.

2 Jan 2008

Patient knowledge of heart risk profile may help improve cholesterol management

Patients who discuss their coronary risk profiles with their physicians may respond better to treatment for cholesterol disorders, according to a report in the November 26 issue of Archives of Internal Medicine.

27 Nov 2007

GlaxoSmithKline to acquire Reliant Pharmaceuticals

GlaxoSmithKline and Reliant Pharmaceuticals Inc. have announced that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.

21 Nov 2007

New investigational combination pill improves multiple cholesterol disorders

Patients treated with a new investigational combination pill showed significant improvements in cholesterol, triglycerides and other key lipids that lead to heart disease, according to results presented at the American Heart Association's Scientific Sessions.

5 Nov 2007

Abbott and AstraZeneca confirm Phase III clinical trials of Fenofibrate ABT-335 and Crestor as fixed-dose combination

Abbott and AstraZeneca confirmed they will advance the development of Abbott's next-generation fenofibrate ABT-335 and AstraZeneca's CRESTOR (rosuvastatin calcium) in a fixed-dose combination treatment into Phase III clinical trials.

3 Sep 2007

Pfizer and Bristol-Myers Squibb finalize agreement on metabolic disorders program

Pfizer Inc. and Bristol-Myers Squibb Company have announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007.

28 Aug 2007

Genomic factors may play a role in alcohol and tobacco use

Alcohol and smoking can be harmful, if not deadly. While the desire for these substances can be due to environmental cues, genomic factors also play an important role.

13 Aug 2007

Quality of treatment guidelines

Practising physicians are nowadays presented with official guidelines on the treatments they should give their patients.

7 Aug 2007

Hydroxychloroquine may reduce risk of diabetes in patients with rheumatoid arthritis

Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA .

11 Jul 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007

Abbott submits NDA for combination Niaspan/Simvastatin tablet

Abbott has submitted a New Drug Application to the Food and Drug Administration for a fixed-dose combination (Simcor) of Niaspan (extended-release niacin) and simvastatin.

24 Apr 2007

Lexicon-Genentech reveals potential therapeutic targets

Lexicon Genetics Incorporated has announced that data was presented highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular Sciences 13th Annual Conference & Exhibition in Montreal, Canada.

19 Apr 2007